Literature DB >> 26151233

Evaluation of Severe Combined Immunodeficiency and Combined Immunodeficiency Pediatric Patients on the Basis of Cellular Radiosensitivity.

Pavel Lobachevsky1, Lisa Woodbine2, Kuang-Chih Hsiao3, Sharon Choo3, Chris Fraser4, Paul Gray5, Jai Smith1, Nickala Best6, Laura Munforte6, Elena Korneeva2, Roger F Martin1, Penny A Jeggo2, Olga A Martin7.   

Abstract

Pediatric patients with severe or nonsevere combined immunodeficiency have increased susceptibility to severe, life-threatening infections and, without hematopoietic stem cell transplantation, may fail to thrive. A subset of these patients have the radiosensitive (RS) phenotype, which may necessitate conditioning before hematopoietic stem cell transplantation, and this conditioning includes radiomimetic drugs, which may significantly affect treatment response. To provide statistical criteria for classifying cellular response to ionizing radiation as the measure of functional RS screening, we analyzed the repair capacity and survival of ex vivo irradiated primary skin fibroblasts from five dysmorphic and/or developmentally delayed pediatric patients with severe combined immunodeficiency and combined immunodeficiency. We developed a mathematical framework for the analysis of γ histone 2A isoform X foci kinetics to quantitate DNA-repair capacity, thus establishing crucial criteria for identifying RS. The results, presented in a diagram showing each patient as a point in a 2D RS map, were in agreement with findings from the assessment of cellular RS by clonogenic survival and from the genetic analysis of factors involved in the nonhomologous end-joining repair pathway. We provide recommendations for incorporating into clinical practice the functional assays and genetic analysis used for establishing RS status before conditioning. This knowledge would enable the selection of the most appropriate treatment regimen, reducing the risk for severe therapy-related adverse effects.
Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26151233      PMCID: PMC4597279          DOI: 10.1016/j.jmoldx.2015.05.004

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  63 in total

Review 1.  Histone H2AX in DNA damage and repair.

Authors:  Olga A Sedelnikova; Duane R Pilch; Christophe Redon; William M Bonner
Journal:  Cancer Biol Ther       Date:  2003 May-Jun       Impact factor: 4.742

2.  GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence.

Authors:  Olga A Sedelnikova; William M Bonner
Journal:  Cell Cycle       Date:  2006-12-15       Impact factor: 4.534

3.  An instance of clinical radiation morbidity and cellular radiosensitivity, not associated with ataxia-telangiectasia.

Authors:  P N Plowman; B A Bridges; C F Arlett; A Hinney; J E Kingston
Journal:  Br J Radiol       Date:  1990-08       Impact factor: 3.039

4.  A radiation-induced gene expression signature as a tool to predict acute radiotherapy-induced adverse side effects.

Authors:  Claudia Mayer; Odilia Popanda; Burkhard Greve; Eberhard Fritz; Thomas Illig; Friederike Eckardt-Schupp; Maria Gomolka; Axel Benner; Peter Schmezer
Journal:  Cancer Lett       Date:  2011-01-13       Impact factor: 8.679

5.  Neonatal bone marrow transplantation for severe combined immunodeficiency.

Authors:  L Kane; A R Gennery; B N Crooks; T J Flood; M Abinun; A J Cant
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-09       Impact factor: 5.747

6.  A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation.

Authors:  Mirjam van der Burg; Lieneke R van Veelen; Nicole S Verkaik; Wouter W Wiegant; Nico G Hartwig; Barbara H Barendregt; Linda Brugmans; Anja Raams; Nicolaas G J Jaspers; Malgorzata Z Zdzienicka; Jacques J M van Dongen; Dik C van Gent
Journal:  J Clin Invest       Date:  2005-12-15       Impact factor: 14.808

7.  Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency.

Authors:  D Moshous; I Callebaut; R de Chasseval; B Corneo; M Cavazzana-Calvo; F Le Deist; I Tezcan; O Sanal; Y Bertrand; N Philippe; A Fischer; J P de Villartay
Journal:  Cell       Date:  2001-04-20       Impact factor: 41.582

Review 8.  The many faces of Artemis-deficient combined immunodeficiency - Two patients with DCLRE1C mutations and a systematic literature review of genotype-phenotype correlation.

Authors:  Pamela P Lee; Lisa Woodbine; Kimberly C Gilmour; Shahnaz Bibi; Catherine M Cale; Persis J Amrolia; Paul A Veys; E Graham Davies; Penny A Jeggo; Alison Jones
Journal:  Clin Immunol       Date:  2013-08-27       Impact factor: 3.969

9.  Intrinsic radiosensitivity of normal human fibroblasts and lymphocytes after high- and low-dose-rate irradiation.

Authors:  F B Geara; L J Peters; K K Ang; J L Wike; S S Sivon; R Guttenberger; D L Callender; E P Malaise; W A Brock
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

Review 10.  The clinical impact of deficiency in DNA non-homologous end-joining.

Authors:  Lisa Woodbine; Andrew R Gennery; Penny A Jeggo
Journal:  DNA Repair (Amst)       Date:  2014-03-11
View more
  5 in total

1.  DCLRE1C (ARTEMIS) mutations causing phenotypes ranging from atypical severe combined immunodeficiency to mere antibody deficiency.

Authors:  Timo Volk; Ulrich Pannicke; Ismail Reisli; Alla Bulashevska; Julia Ritter; Andrea Björkman; Alejandro A Schäffer; Manfred Fliegauf; Esra H Sayar; Ulrich Salzer; Paul Fisch; Dietmar Pfeifer; Michela Di Virgilio; Hongzhi Cao; Fang Yang; Karin Zimmermann; Sevgi Keles; Zafer Caliskaner; S Ükrü Güner; Detlev Schindler; Lennart Hammarström; Marta Rizzi; Michael Hummel; Qiang Pan-Hammarström; Klaus Schwarz; Bodo Grimbacher
Journal:  Hum Mol Genet       Date:  2015-10-16       Impact factor: 6.150

2.  Compromized DNA repair as a basis for identification of cancer radiotherapy patients with extreme radiosensitivity.

Authors:  Pavel Lobachevsky; Trevor Leong; Patricia Daly; Jai Smith; Nickala Best; Jonathan Tomaszewski; Ella R Thompson; Na Li; Ian G Campbell; Roger F Martin; Olga A Martin
Journal:  Cancer Lett       Date:  2016-09-28       Impact factor: 8.679

3.  Biomarkers of DNA Damage Response Enable Flow Cytometry-Based Diagnostic to Identify Inborn DNA Repair Defects in Primary Immunodeficiencies.

Authors:  Kerstin Felgentreff; Ulrich Baumann; Christian Klemann; Catharina Schuetz; Dorothee Viemann; Martin Wetzke; Ulrich Pannicke; Sandra von Hardenberg; Bernd Auber; Klaus-Michael Debatin; Eva-Maria Jacobsen; Manfred Hoenig; Ansgar Schulz; Klaus Schwarz
Journal:  J Clin Immunol       Date:  2021-10-30       Impact factor: 8.317

4.  Evaluation of Capability and Relationship of Different Radiobiological Endpoints for Radiosensitivity Prediction in Human Tumor Cell Lines Compared with Clonogenic Survival.

Authors:  Fatemeh Pakniyat; Hassan Ali Nedaie; Hossein Mozdarani; Aziz Mahmoudzadeh; Somayeh Gholami
Journal:  J Biomed Phys Eng       Date:  2022-04-01

Review 5.  Clinical and Functional Assays of Radiosensitivity and Radiation-Induced Second Cancer.

Authors:  Mohammad Habash; Luis C Bohorquez; Elizabeth Kyriakou; Tomas Kron; Olga A Martin; Benjamin J Blyth
Journal:  Cancers (Basel)       Date:  2017-10-27       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.